Scotland ploughs £40 million into CHD (coronary heart disease) and stroke:
This article was originally published in Clinica
Executive Summary
Scottish health minister Malcolm Chisholm has allocated an additional £40m ($63m) to help meet plans to reduce the maximum waits for angiography, heart surgery and angioplasty. Under plans announced in September 2001, Scotland aims to reduce the maximum patient waiting time for angiography from 12 to eight weeks by 2004, and for heart surgery or angioplasty from 24 to 18 weeks by 2004. The initiative was announced today (October 3 2002) as part of Scotland's first Coronary Heart Disease and Stroke strategy. This aims to reduce deaths from CHD and Stroke among the under 75s by 50% between 1995 and 2010.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.